

Emerging Therapies for Rel / Ref CLL

ASH 2022

- **ALPINE: Zanubrutnib superior PFS and ORR over ibrutinib in R/R CLL**
- **Combined IBR + VEN (CLARITY) highly active in R/R CLL**
- **Venetoclax consolidation feasible in patients on IBR \geq 12 months with potential for clinical benefit (discontinue treatment, long remission)**
- **Pirtobrutinib effective for prior BTKi-treated CLL, including with C481 mutation**
- **BTK-degrader (NX-2127) tolerated with activity – novel mechanism of action**
- **New BCL2 inhibitors (BGB-11417 and Lisafoclax) have activity and being combined with cBTKi and CD20 mAb**
- **Protein kinase C-beta inhibitor (PKC β i) - MS-553 tolerated with activity in BTKi-treated CLL being evaluated alone and in combinations**